Search
Showing 1 - 16 of 16 results
High Risk for Breast Cancer: Methods and Schedules to Ensure Optimal Screening
Hematologist-oncologist Elham Vosoughi, MD, starts with an update on breast cancer stats, noting that incidence in the United States is increasing by 1% every year – with an even sharper rise for women under 50.Making Sense of MGUS: How to Detect Plasma Cell Disorders and Assess Associated Risks
Affecting up to 5% of the U.S. population (and increasingly common with age), monoclonal gammopathy of undetermined significance (MGUS) raises the risk of multiple myeloma, but – as its full name suggests – it can be hard to say by how much.Advances (and Uncertainties) in Oncology: Current and Future Roles of Antibody Drug Conjugates
Focusing on common bladder, lung and breast cancers, three UCSF oncologists describe how antibody drug conjugates (ADCs) are changing the treatment landscape, especially for refractory casesNew Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions
These four collaborative talks from UCSF and John Muir Health specialists shine a light on recent study results that should inform treatment planning for patients with a variety of GI, breast, lung and blood cancers.Advances in Breast Cancer Care: Individualized Screening, Treatments and Follow-Up
Karen Goodwin, DO, covers everything from how to answer patients’ questions on mammogram frequency to how to counsel them on breast cancer prevention.Navigating the Maze of Breast Cancer Guidelines: Efficient Paths to Personalized Screening
To help PCPs address patients’ breast cancer screening concerns, surgeon Shoko Emily Abe, MD, FACS, breaks down the multitude of screening directives and modalities, with a focus on the needs of those at average risk and those with dense breast tissue.Lung Cancer Screening: Who, How and When to Refer
†horacic radiologist Brett M. Elicker, MD, and thoracic surgeon Johannes Kratz, MD, present about current lung cancer screening guidelines: who, how, and when to refer.UCSF Osher Center Overview: Integrative Medicine’s Value for Providers and Patients
Sanford C. Newmark, MD, medical director of the UCSF Osher Center for Integrative Medicine, explains what integrative medicine is (hint: it’s neither “alternative medicine” nor homeopathy) and how referred patients can benefit from its proven techniques.Cancer Center Grand Rounds Series
Neuro-Oncology Support Presentations
Educational lectures that are tailored for people with brain tumors or their caregiversCancer Immunotherapy: Promise and Pitfalls
Oncologist David Oh speaks at the October 2017 Bay Area Breast Cancer Forum about key developments in immunotherapy like immune checkpoint inhibitors and T-cell therapies, plus its use in experimental approaches to breast cancer treatment.Salivary Gland Transfer for Head & Neck Cancer Patients
Discover the surprising way a simple surgery can vastly improve quality of life for head and neck cancer patients after radiation treatment. How? By moving the submandibular gland out of the way of the most intense radiation to prevent xerostomia.The Human Microbiome and Breast Cancer
Immunologist Michael Campbell and breast cancer surgeon Laura Esserman speak at the April 2017 Bay Area Breast Cancer Forum about the human biome, how it’s being studied and how it relates to breast cancer prevention and treatment.Updates from the American Society of Clinical Oncology (ASCO) 2017
A June 2017 Bay Area Breast Cancer Forum discussion of updates from the ASCO annual meeting, covering PARP inhibitors, germline BRCA mutations, HER2-positive cancer, patient-reported outcomes, immunotherapy and more. Moderator: Dr. Hope RugoPersonalized Therapy for Early-Stage Lung Cancer at UCSF
Follow the journey of a UCSF patient with early-stage, high-risk lung cancer, from history to treatment and prognosis, including how surgeons chose to do a robotic assisted VATS lobectomy and an analysis of how well chemo is likely to work for her.Multiple Myeloma: Cutting-Edge Induction and Maintenance Therapies Lead to Improved Response Rates and Survival for Newly Diagnosed Patients
Take a deep dive into therapy options for newly diagnosed myeloma patients: whether three drugs are better than two, the case for lenalidomide maintenance therapy, the many improvements in induction treatment, the future of immunotherapy, and more.